|Videos|February 4, 2021
Tarsus execs discuss origins, treating Demodex blepharitis
Author(s)OT Staff Reports
Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
2
Lesion growth rate reduction tops retina specialists' geographic atrophy treatment priorities
3
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
4
Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities
5






















